Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371701 | 0.92 | FGFR1 (0.41) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL12371718 | 0.88 | POLB (0.41) | POLBEGFRALOX15TSHRHTT | |
| SCHEMBL12371666 | 0.86 | JAK2 (0.44) | JAK2JAK3 | |
| SCHEMBL12371788 | 0.85 | POLB (0.44) | QPCTJAK2JAK3POLBEGFR | |
| SCHEMBL13620251 | 0.85 | JAK2 (0.43) | JAK2JAK3 | |
| SCHEMBL13620265 | 0.84 | POLB (0.44) | QPCTJAK2JAK3POLBALOX15 | |
| SCHEMBL13620074 | 0.81 | ADORA2A (0.50) | JAK2JAK3 | |
| SCHEMBL13620406 | 0.80 | POLB (0.41) | QPCTPOLBEGFRALOX15TSHR | |
| SCHEMBL13608435 | 0.79 | FGFR1 (0.45) | POLBEGFRALOX15TSHRHTT | |
| SCHEMBL12371799 | 0.79 | SMN1; SMN2 (0.43) | QPCTPOLBEGFRALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | QPCT 2918/4885JAK2 1072/4885JAK3 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.